Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HAV regimen versus standard regimens for newly diagnosed non-APL acute myeloid leukemia
ChiCTR2100048208Phase 3Recruiting
- Sponsor
- First Affiliated Hospital of Chongqing Medical University
- Start
- Jul 2021
- Modality
- Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of venetoclax, homoharringtonine and cytarabine in acute myeloid leukemia (AML) (2 arms), sponsored by First Affiliated Hospital of Chongqing Medical University. Primary endpoints: Complete response rate and Safety. Started Jul 2021; status: recruiting.
02
Drugs
venetoclaxhomoharringtoninecytarabine
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on ChiCTR2100048208.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100048208.